<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">33781159</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-1753</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of dermatological treatment</Title>
          <ISOAbbreviation>J Dermatolog Treat</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Treatment of tardive dyskinesia: a review and update for dermatologists managing delusions of parasitosis.</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>5</EndPage>
          <MedlinePgn>1-5</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/09546634.2021.1892025</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">This article introduces to the dermatology provider two medications for the treatment of tardive dyskinesia (TD), which were the first medications approved by the US FDA specifically for the treatment of TD. In addition to describing these two new medications, this article will also provide a focused review of the pathogenesis of TD, as well as non-FDA-approved treatments, which have been tried prior to the advent of these medications.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">A PubMed search was conducted and articles were reviewed by the senior authors and included if they were relevant for dermatologists regarding etiology, symptoms, risk, and treatment of TD.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">One of the most widely accepted explanations of TD involves the concept of 'dopamine receptor hypersensitivity state.' There are several other less well substantiated proposed pathogenic pathways of TD. The clinical manifestation is characterized by involuntary movements. Prevention includes switching to a 2nd generation agent or using the lowest dose possible for the shortest amount of time. Two new FDA-approved medications for TD are also discussed and reviewed.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TD now has FDA-approved medications for treatment. Now, there is even more reason for the dermatologist to have increased confidence when treating delusions of parasitosis (DOP) with antipsychotic agents.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brownstone</LastName>
            <ForeName>Nicholas</ForeName>
            <Initials>N</Initials>
            <Identifier Source="ORCID">0000-0002-1187-1712</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koo</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Dermatolog Treat</MedlineTA>
        <NlmUniqueID>8918133</NlmUniqueID>
        <ISSNLinking>0954-6634</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Morgellons disease</Keyword>
        <Keyword MajorTopicYN="N">Psychodermatology</Keyword>
        <Keyword MajorTopicYN="N">delusions of parasitosis</Keyword>
        <Keyword MajorTopicYN="N">pimozide</Keyword>
        <Keyword MajorTopicYN="N">psychocutaneous medicine</Keyword>
        <Keyword MajorTopicYN="N">tardive dyskinesia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33781159</ArticleId>
        <ArticleId IdType="doi">10.1080/09546634.2021.1892025</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
